Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137129 | 0.86 | KMT2A (0.44) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL14696044 | 0.80 | KMT2A (0.42) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL6346242 | 0.77 | SLC22A2 (0.39) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL2536293 | 0.74 | SLC22A2 (0.46) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL3813603 | 0.70 | KMT2A (0.48) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL9670646 | 0.68 | KMT2A (0.42) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL14418633 | 0.68 | KMT2A (0.42) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL5597864 | 0.68 | KMT2A (0.42) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL14695859 | 0.68 | SLC22A2 (0.50) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 | |
| SCHEMBL5301476 | 0.68 | SLC22A2 (0.50) | KMT2AMEN1CYP2D6CYP2C19SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137774-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC COMPONENT USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1930327-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC COMPONENT USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137774-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC COMPONENT USING SAME | GJA1, CDH1, OR10J3 | KMT2A 3147/4885MEN1 3801/4885CYP2D6 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.